Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more
Solvonis Therapeutics plc (SVNS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.048x
Based on the latest financial reports, Solvonis Therapeutics plc (SVNS) has a cash flow conversion efficiency ratio of -0.048x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-149.00K) by net assets (GBX3.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Solvonis Therapeutics plc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Solvonis Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Solvonis Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solvonis Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crown Place VCT PLC
LSE:CRWN
|
-0.003x |
|
BRIDGEFORT CAPITAL LIMITED CLASS B
XZIM:BFCB
|
N/A |
|
WILLDALE LIMITED
XZIM:WILD
|
N/A |
|
STAR AFRICA CORPORATION LIMITED
XZIM:SACL
|
N/A |
|
BRIDGEFORT CAPITAL LIMITED
XZIM:BFCA
|
N/A |
|
PYX Resources Limited
LSE:PYX
|
-0.001x |
|
SigmaBroadband Co
PINK:SGRB
|
-0.010x |
|
Seneca Growth Capital VCT PLC
LSE:HYG
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Solvonis Therapeutics plc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Solvonis Therapeutics plc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX3.08 Million | GBX-1.13 Million | -0.366x | +40.04% |
| 2023-12-31 | GBX2.03 Million | GBX-1.24 Million | -0.611x | -17.91% |
| 2022-12-31 | GBX4.55 Million | GBX-2.36 Million | -0.518x | -65.67% |
| 2021-12-31 | GBX812.00K | GBX-254.00K | -0.313x | -48334.98% |
| 2021-05-31 | GBX1.54 Million | GBX1.00K | 0.001x | +100.58% |
| 2020-05-31 | GBX1.70 Million | GBX-192.00K | -0.113x | +54.86% |
| 2019-05-31 | GBX2.24 Million | GBX-560.00K | -0.250x | -78.11% |
| 2018-05-31 | GBX2.94 Million | GBX-413.00K | -0.140x | -- |